We are live on ! Find out more
CTKB icon

Cytek Biosciences
CTKB

165 hedge funds and large institutions have $372M invested in Cytek Biosciences in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 68 increasing their positions, 51 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

196% more call options, than puts

Call options by funds: $71K | Put options by funds: $24K

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

33% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 51

6% more funds holding

Funds holding: 155 → 165 (+10)

2.37% more ownership

Funds ownership: 64.15% → 66.53% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less capital invested

Capital invested by funds: $414M → $372M (-$42.5M)

Holders
165
Holders Change
+10
Holders Change %
+6.45%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
68
Reduced
51
Closed
11
Calls
$71K
Puts
$24K
Net Calls
+$47K
Net Calls Change
+$37K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$7.27M
2
Boston Partners
Boston Partners
Massachusetts
+$3.75M
3
CP
CenterBook Partners
Connecticut
+$3.45M
4
SC
Simcoe Capital
Washington
+$2.76M
5
Goldman Sachs
Goldman Sachs
New York
+$2.62M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.86M
2
BCM
Brown Capital Management
Maryland
-$2.8M
3
TCM
Topline Capital Management
California
-$1.78M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.3M
5
UBS Group
UBS Group
Switzerland
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
126
Sterling Capital Management
North Carolina
$17.1K -$13.7K -2,903 -43%
Nisa Investment Advisors
127
Nisa Investment Advisors
Missouri
$16.4K +$477 +101 +3%
Simplex Trading
128
Simplex Trading
Illinois
$14.1K +$5.77K +1,223 +61%
Optiver Holding
129
Optiver Holding
Netherlands
$13.9K +$15K +3,175 New
SL
130
Salomon & Ludwin
Virginia
$12.2K +$10.6K +2,241 +487%
VCM
131
Versant Capital Management
Arizona
$12K +$10.9K +2,300 +529%
EP
132
Essential Partners
California
$11.3K +$3.06K +648 +34%
Royal Bank of Canada
133
Royal Bank of Canada
Ontario, Canada
$10K -$15.2K -3,226 -58%
Group One Trading
134
Group One Trading
Illinois
$9.61K +$3.31K +700 +47%
EWA
135
EverSource Wealth Advisors
Alabama
$7.96K +$1.14K +242 +15%
SSG
136
Summit Securities Group
New York
$7.45K +$8.04K +1,704 New
PWMG
137
Private Wealth Management Group
New Jersey
$7.4K – – –
GI
138
GAMMA Investing
California
$7.13K +$5.26K +1,114 +215%
UB
139
UMB Bank
Missouri
$6.14K +$109 +23 +2%
AF
140
Allworth Financial
California
$6.08K +$1.61K +341 +33%
Osaic Holdings
141
Osaic Holdings
Arizona
$4.99K +$4.84K +1,025 +876%
IA
142
IFP Advisors
Florida
$4.31K +$1.3K +276 +39%
TWD
143
True Wealth Design
Ohio
$3.11K +$463 +98 +16%
Bessemer Group
144
Bessemer Group
New Jersey
$3K – – –
HFS
145
Hantz Financial Services
Michigan
$3K +$1.41K +298 +103%
UBS AM
146
UBS AM
Illinois
$2.54K -$1.18K -250 -30%
US Bancorp
147
US Bancorp
Minnesota
$2.43K +$486 +103 +23%
LFG
148
Larson Financial Group
Missouri
$2.06K +$1.97K +417 +772%
S
149
SignatureFD
Georgia
$1.91K – – –
RIL
150
Rothschild Investment LLC
Illinois
$1.72K +$557 +118 +43%
3 4 5
6
7

CTKB Hedge Fund Activity: Q1 2026 in Review

165 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2026, worth a combined $372M — down 10% from $414M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CTKB positions and 11 closed out — a net gain of 13 holders — while 68 added to existing stakes and 51 trimmed.

The largest buyer was Millennium Management, adding an estimated $7.27M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.86M sold.

  • 165 institutional investors held Cytek Biosciences (CTKB) as of Q1 2026, up from 155 in Q4 2025.
  • Funds reported $372M of Cytek Biosciences stock for Q1 2026, down 10% quarter-over-quarter.
  • 24 funds opened new Cytek Biosciences positions in Q1 2026 and 11 closed out, a net change of +13 holders.
  • The largest Cytek Biosciences buyer in Q1 2026 was Millennium Management, an estimated $7.27M added.
  • The largest Cytek Biosciences seller in Q1 2026 was Wellington Management Group, an estimated $3.86M sold.

Based on aggregated 13F filings for Q1 2026.